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Cholesteryl Ester Transfer Protein Inhibition as a Safe and Effective Means
for Treating Dyslipidemia and Potentially Reducing Cardiovascular Risk in
Patients with CHD or Risk Equivalents
Abstract
Background: Secondary prevention of coronary events in patients with known CHD and dyslipidemia has
traditionally been focused on decreasing LDL-C through the use of statins. However, significant risk remains
in individuals whose LDL-C has been optimized but HDL-C remains low. A new class of medications,
cholesteryl ester transfer protein inhibitors, is effective at significantly increasing HDL-C and potentially
reducing cardiovascular risk in such patients. There are currently three CETP inhibitors being developed, two
of which have been studied for safety and efficacy in patients with CHD or risk equivalents: anacetrapib and
dalcetrapib. Following the safety concerns of torcetrapib, both study medications have demonstrated that they
do not have the same off-target effects as those seen in the ILLUMINATE trial.
Methods: A systematic search of the literature was performed utilizing three databases: MEDLINE,
CINAHL, and Evidence-Based Medicine Reviews Multifile. Four double-blind, placebo-controlled clinical
trials met the inclusion and exclusion criteria for review.
Results: Anacetrapib demonstrated an impressive 138.1% greater increase in HDL-C, and 39.8% greater
reduction in LDL-C as compared to placebo without any differences in tolerability or AEs. Although not a
pre-determined end-point, there was a significant reduction in revascularization rates with anacetrapib as
compared to placebo as well (8 vs 21). Dalcetrapib was also shown to be safe and effective, although its lipid-
modifying effects were significantly less than those seen with anacetrapib. The dal-PLAQUE trial also
suggested a potential benefit in reducing atherosclerotic lesions in the carotid arteries. Neither medication was
shown to increase blood pressure or cardiovascular morbidity or mortality.
Conclusion: Both anacetrapib and dalcetrapib have established themselves as safe and effective agents for
increasing HDL-C, and to a lesser extent decreasing LDL-C. Although short-term data suggests a potential
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NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
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Abstract   
 
Background:  Secondary prevention of coronary events in patients with known CHD and 
dyslipidemia has traditionally been focused on decreasing LDL-C through the use of statins. 
However, significant risk remains in individuals whose LDL-C has been optimized but HDL-C 
remains low. A new class of medications, cholesteryl ester transfer protein inhibitors, is effective 
at significantly increasing HDL-C and potentially reducing cardiovascular risk in such patients. 
There are currently three CETP inhibitors being developed, two of which have been studied for 
safety and efficacy in patients with CHD or risk equivalents: anacetrapib and dalcetrapib. 
Following the safety concerns of torcetrapib, both study medications have demonstrated that they 
do not have the same off-target effects as those seen in the ILLUMINATE trial. 
Method:  A systematic search of the literature was performed utilizing three databases: 
MEDLINE, CINAHL, and Evidence-Based Medicine Reviews Multifile. Four double-blind, 
placebo-controlled clinical trials met the inclusion and exclusion criteria for review.  
Results:  Anacetrapib demonstrated an impressive 138.1% greater increase in HDL-C, and 39.8% 
greater reduction in LDL-C as compared to placebo without any differences in tolerability or 
AEs. Although not a pre-determined end-point, there was a significant reduction in 
revascularization rates with anacetrapib as compared to placebo as well (8 vs 21). Dalcetrapib 
was also shown to be safe and effective, although its lipid-modifying effects were significantly 
less than those seen with anacetrapib. The dal-PLAQUE trial also suggested a potential benefit in 
reducing atherosclerotic lesions in the carotid arteries. Neither medication was shown to increase 
blood pressure or cardiovascular morbidity or mortality. 
Conclusion:  Both anacetrapib and dalcetrapib have established themselves as safe and effective 
agents for increasing HDL-C, and to a lesser extent decreasing LDL-C. Although short-term data 
suggests a potential cardioprotective benefit with CETP inhibition, definitive conclusions 
regarding risk reduction in patients with CHD will be determined following the outcomes of the 
current phase III clinical trials.  





Thank you to my little sister Andrea, who continues to show me that anything is possible with a 
little gnashing of the teeth and clawing of the nails. You amaze me. Of course, this is all made 
possible by a grant from my parents: thank you for my life and your patience. My friends have 
kept me very sane and a little drunk through this adventure known as PA school, I couldn’t have 
done it without you. Last but not least, I would like to thank hydrogen. It is through your simple 
elegance that all things are made. 
  





Table of Contents…………………………………………………………………………………..5 
List of Tables…………………………………………………………………………………….5 
List of Figures ...….….…………………………………………………………………………....6 











List of Tables  
 
Table I:       Characteristics of Reviewed Studies  
Table II:     Summary of Findings 
 
List of Figures 
 
Figure I: Diagram of lipid transport and the action of CETP 
 
List of Abbreviations 
 
ACS……………………………………………………………..Acute coronary syndrome 
AE…………………………………………………………………………...Adverse event 
ALP…………………………………………………………………..Alkaline phosphatase 
CETP…………………………………………………….Cholesteryl ester transfer protein 





HDL-C…………………………………….…………High-density lipoprotein cholesterol 
hs-CRP…………………………………………………high-sensitivity C-reactive protein 
IDL-C………………………………………...Intermediate-density lipoprotein cholesterol 
LDL-C..........................................................................Low-density lipoprotein cholesterol 
MI………………………………………………………………...…Myocardial Infarction 
  
NCEP ATP III………National Cholesterol Education Program Adult Treatment Panel III 
PAD……………………………………………………………..Peripheral arterial disease 
SAE…………………………………………………………………..Severe adverse event 















Cholesteryl Ester Transfer Protein Inhibition as a Safe and Effective 
Means of Treating Dyslipidemia and Potentially Reducing 
Cardiovascular Risk in Patients with CHD or Risk Equivalents: A 
Systematic Review  
BACKGROUND 
Although the rates of cardiovascular related deaths have declined significantly in 
recent decades the burden of disease remains high, accounting for one-third of all deaths 
in America, and is still the number one cause of death worldwide.1
 
There are several 
established risk factors for coronary heart disease (CHD) in the general population, some 
of which are modifiable targets for medical therapy. Elevated low-density lipoprotein 
(LDL-C) and depressed high-density lipoprotein (HDL-C) are two such risk factors. 
Treating dyslipidemia as a means of secondary prevention to reduce the risk of coronary 
events in individuals with known CHD has traditionally been focused on decreasing 
LDL-C through the use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors 
(statins). Multiple clinical trials have demonstrated the efficacy of statins in reducing 
LDL-C and to a varying extent secondary events in individuals with known CHD2-5 
however, significant risk remains with individuals in whom HDL-C remains low despite 
treatment with statins.6, 77, 8 This phenomenon is further supported by a meta-analysis 
which demonstrated HDL-C to be predictive of cardiovascular events despite having an 
LDL-C of 70 mg/dl or less.8 
Unfortunately, few options currently exist for clinicians to treat patients with CHD 
and dyslipidemia in whom HDL-C remains below the current recommended guidelines 
( 40 mg/dl in men and  50 mg/dl in women).9 Statins, fibrates, and nicotinic acid have 
all been shown to modestly increase HDL-C.10 A recent meta-analysis demonstrated 
  
nicotinic acid to be the most effective agent available for increasing HDL-C (an average 
increase of 16%)11 however, many patients are intolerant to its common side-effects of 
flushing and pruritus. The desire for a more effective and well-tolerated medication for 
increasing HDL-C has led to the development of a novel class of medications known as 
cholesteryl ester transfer protein (CETP) inhibitors.  
 
Mechanism of Action 
Cholesteryl ester transfer protein is a glycoprotein that is primarily secreted by the 
liver and is intimately involved in the cholesterol transport pathways, specifically in 
reverse cholesterol transport.12 In circulation, CETP is frequently bound to HDL-C 
molecules.12 The role of CETP is to facilitate the transfer of cholesterol esters from HDL-
C to chylomicrons, very low-density lipoprotein (VLDL-C), and LDL-C in exchange for 
triglycerides.13 Following the transfer from HDL-C to LDL-C, cholesterol esters are 
bound for one of two fates: return to the liver or delivery to peripheral tissues following 
oxidation.14, 15 It is through this second pathway in which CETP is thought to promote the 
atherosclerotic process and is the basis for CETP inhibition as a means of preventing the 
progression of atherosclerosis and reducing CHD risk. As CETP activity decreases, 
HDL-C increases, thereby increasing cholesterol efflux out of tissue cells to be returned 
to the liver for excretion into bile.16 In addition to its role in reverse cholesterol transport, 
HDL-C is believed to have anti-inflammatory, anti-oxidative, anti-thrombotic, anti-
infectious, and vasodilatory effects, which contribute to its cardioprotective properties.17-
21 The pathway of reverse cholesterol transport and basis for CETP inhibition are 
illustrated in figure 1.  
  
Development 
The first CETP inhibitor investigated was torcetrapib, manufactured by Pfizer®. 
Early clinical trials demonstrated promising results with significant increases in HDL-C 
and reductions of LDL-C.22, 23 The ILLUMINATE trial was a phase III clinical trial 
designed to evaluate the safety and efficacy of torcetrapib in individuals with known 
cardiovascular disease (CVD) or who were at high-risk for CVD.24 In December 2006, 
the ILLUMINATE trial was terminated early due to an observed increase in morbidity 
and mortality in patients taking the study medication.24 Increases in systolic blood 
pressure, serum sodium, bicarbonate and aldosterone as well as decreases in potassium 
were noted in treatment patients. More importantly, there was an increased risk for 
cardiovascular events and death (hazard ratio 1.25 and 1.58, respectively).24 Initially there 
were concerns that the mechanism behind the deleterious effects of torcetrapib may have 
been mediated through its effects on CETP activity. It has since been determined that 
there were multiple off-target effects of torcetrapib unrelated to CETP inhibition, most 
significantly on the renin-angiotensin-aldosterone system (RAAS).25-28 There are 
currently three CETP-inhibitors in development: anacetrapib (Merck®), dalcetrapib 
(Roche®), and evacetrapib (Eli Lilly®). All three medications have demonstrated safety 
and efficacy in healthy populations,29-34 while anacetrapib and dalcetrapib have 
specifically been tested in individuals with CHD or risk equivalents. It is the purpose of 
this review article to evaluate the safety and efficacy of CETP inhibitors in treating 
dyslipidemia in patients with CHD or risk equivalents and their potential in reducing CV 




A systematic search of the available literature was performed utilizing the databases 
Ovid/MEDLINE, EBSCOhost/CINAHL and the Evidence-Based Medicine Reviews 
Multifile using the MeSH terms and key words CETP inhibitor, cholesteryl ester transfer 
protein inhibitor, anacetrapib, dalcetrapib and evacetrapib combined with the modifier 
‘or’. All searches were limited to articles published in the English language.  
Randomized, double-blind, placebo-controlled clinical trials evaluating the safety 
and efficacy of various CETP inhibitors in individuals with known CHD or risk 
equivalents were included. Articles that were excluded were those evaluating the safety 
and efficacy of the medication torcetrapib due to the well known and established harmful 
effects of this medication. Studies that did not fit inclusion criteria were utilized solely 
for the background and discussion of this review.  
RESULTS 
The systematic search of the literature from three databases yielded a total of 284 
articles. The resulting articles from the search were compiled and further screened for 
relevance to subject matter. Excluded were 276 articles, the remaining eight articles 
yielded four duplicates. Four randomized, double-blind, placebo-controlled clinical trials 
met inclusion and exclusion criteria and were evaluated for systematic review.  
An additional randomized, double-blind, placebo-controlled clinical trial was cited 
several times throughout the literature search. The The dal-VESSEL35 article was 




Safety of anacetrapib in patients with or at high risk for coronary heart disease 
Cannon et al36 evaluated the safety and efficacy of anacetrapib in individuals with 
known CHD or who were at high risk for CHD. High risk was defined as those 
individuals with a Framingham Risk Score >20% per ten years. Participants were 18 to 
80 years old and had an LDL-C of 50-100 mg/dl while being treated with a statin (99.3% 
of participants were being treated with a statin) with or without concomitant use of other 
lipid-lowering medications, had an HDL-C of less than 60 mg/dl and a plasma 
triglyceride concentration of 400 mg/dl or less. Patients were excluded if they had severe 
chronic heart failure, hypertension that was uncontrolled, any form of cardiac arrhythmia, 
an episode of acute coronary syndrome (ACS) or had underwent revascularization within 
the past three months, had active hepatobiliary disease, significantly impaired renal 
function, were receiving anticoagulation therapy with Coumadin or any other potent 
modifiers of the CYP3A4 pathway.36  
A total of 153 medical centers in 20 countries screened a total of 2757 patients for 
entry into the study. Of the 2757 patients screened, 1697 were accepted into a placebo 
run-in phase. Those individuals who had a 75% adherence to treatment in the run-in 
phase were allowed to continue with the study. A total of 1623 patients were included in 
the study. Patients were prognostically balanced at baseline and throughout the course of 
the study. In a double-blinded fashion, participants were randomly assigned at a 1:1 ratio 
to receive either anacetrapib 100 mg or equivalent placebo orally once daily with food. 
Study participants were then evaluated every six to eight weeks in clinic for monitoring 
of possible adverse reactions, blood pressure measurements as well as venous blood 
draws for lipid measurements and other lab tests to assist in determining the safety of the 
  
study medication. It was predetermined that if a patient’s LDL-C was found to be less 
than 25 mg/dl from two consecutive assays that the study medication would be 
discontinued. If a patient’s LDL-C was found to be elevated greater than 115 mg/dl on 
two consecutive assays and adherence was verified, investigators adjusted the patient’s 
non-study lipid-lowering medications (e.g. statins) accordingly. All patients, including 
those who did not complete treatment with the study medication were followed up twelve 
weeks after the termination of the 76 week trial to further assess safety of the study 
medication.36  
The primary end points for the study included percentage change in LDL-C after 24 
weeks of treatment and assessing the safety and side effect profile of the study 
medication. Of particular interest regarding indicators of possible adverse events was 
blood pressure; serum transaminases, creatinine kinase, sodium, potassium, chloride and 
bicarbonate. Predetermined adverse events that were monitored include myalgias, 
rhabdomyolysis, death attributable to cardiovascular causes, nonfatal myocardial 
infarction (MI) or cerebrovascular accident (CVA), unstable angina requiring 
hospitalization and all-cause death. Incidents of ACS requiring revascularization and 
heart failure were recorded but were not part of the predetermined cardiovascular end 
points. Secondary end points included percentage change of LDL-C from baseline to 76 
weeks and HDL-C, calculated total cholesterol, apolipoprotein B and apolipoprotein A-1 
at weeks 24 and 76.36 
The 76 week trial lost 142 of the 811(17.6%) original anacetrapib patients due to 
LDL-C falling below the 25 mg/dl mark, while only one (0.1%) of the control patients 
was withdrawn secondary to low LDL-C. After considering the patients who were 
  
withdrawn due to low LDL-C, the proportion of patients who discontinued the trial was 
balanced between the anacetrapib and placebo groups with 14.6% and 17.4%, 
respectively. Patients took anacetrapib for a mean of 424 days and placebo for a mean of 
483 days. Follow-up in respect to clinical safety end-points was 99.1% and 99.4% for the 
anacetrapib and placebo groups.36 
At week 24, LDL-C had decreased from 81 mg/dl to 45 mg/dl in the anacetrapib 
group compared to placebo which had a decrease from 82 mg/dl at baseline to 77 mg/dl, 
demonstrating a decrease in LDL-C that was 39.8% greater with anacetrapib than that 
with placebo (P<0.001).  HDL-C was increased from 41 mg/dl to 101 mg/dl in the 
anacetrapib group as compared to placebo which had an increase from 40 mg/dl at 
baseline to 46 mg/dl, demonstrating an increase in HDL-C that was 138.1% greater with 
anacetrapib than that with placebo (P<0.001). Non-HDL cholesterol decreased from 
109.7 mg/dl to 69.7 mg/dl in the anacetrapib group compared to placebo which had a 
decrease from 111.1 mg/dl at baseline to 104.8 mg/dl, demonstrating a decrease in non-
HDL cholesterol that was 31.7% greater with anacetrapib than that with placebo 
(P<0.001). Apolipoprotein A-1 plasma concentration increased from 142.5 mg/dl to 
208.0 mg/dl in the anacetrapib group compared to placebo which had an increase from 
142.8 mg/dl at baseline to 144.9 mg/dl, demonstrating an increase in apolipoprotein A-1 
plasma concentration that was 44.7% greater with anacetrapib than that with placebo 
(P<0.001). Apolipoprotein B plasma concentration decreased from 88.4 mg/dl to 70.1 
mg/dl in the anacetrapib group compared to placebo which had an increase from 88.9 
mg/dl at baseline to 89.2 mg/dl, demonstrating a decrease in apolipoprotein B that was 
  
21.0% greater with anacetrapib than that with placebo (P<0.001). All of the changes in 
serum lipid biomarkers were sustained throughout the 76 week trial.36 
There were no significant differences between anacetrapib and placebo in adverse 
events thought to be related to the study medications that resulted in treatment 
discontinuation. There also were no differences in mean change of systolic or diastolic 
blood pressures in the two groups. No significant differences were noted between the 
anacetrapib and placebo groups in regard to serum sodium, potassium, chloride, 
bicarbonate or aldosterone.36 There were no reported cases of rhabdomyolysis in either 
the treatment or placebo groups. There was no significant difference between groups in 
the incidence of reported myalgias or elevations in creatinine kinase. There was however 
significantly fewer cases of elevated transaminases in the anacetrapib group compared to 
placebo (1 vs. 8 respectively). There were a total of 16 (2.0%) cardiovascular adverse 
events in the anacetrapib group during the 76 week trial compared to 21 (2.6%) in the 
placebo group. There was no evidence of an associated 25% increase in cardiovascular 
events that was noted with torcetrapib.24 There were 11 all-cause deaths in the 
anacetrapib group compared with 8 in the placebo group during the 76 week trial. In the 
three months following completion of the trial there was 1 reported death in the 
anacetrapib group and 4 reported in the placebo group, making the total for both groups 
twelve. Although not a predetermined end-point, of particular interest, there were 
significantly fewer patients in the anacetrapib group than placebo that underwent 




Safety and tolerability of dalcetrapib (2009) 
 Stein et al37 evaluated the safety and tolerability of the investigational CETP 
inhibitor dalcetrapib in patients with dyslipidemia, CHD or CHD risk equivalents. This 
phase II clinical trial enrolled a total of 838 patients who participated in five randomized, 
double-blind, placebo-controlled trials. Four of the trials (conducted in the Netherlands), 
had a four-week treatment period and the remaining trial (conducted in the United 
States), had a twelve-week treatment period. Two of the five trials specifically were 
designed to evaluate the study medication in individuals with CHD or CHD risk 
equivalents, as established by the NCEP ATP III guidelines. Two of the three remaining 
trials were designed to evaluate the study medication in individuals with Type II 
hyperlipidemia, while the final trial which had a twelve-week treatment period, evaluated 
the study medication in individuals with low or average HDL-C.  Inclusion criteria can be 
found listed in table 1 of the specified study.  Exclusion criteria were a BMI of 35 or 
greater (40 or greater in the 12-week trial), hypertension that was uncontrolled; diabetes 
(except for the two CHD studies in which it was considered a risk equivalent); significant 
disease of kidneys, liver, heart, brain or arteries; elevated transaminases; active 
pregnancy, breast feeding or a significant likelihood of becoming pregnant; current 
medical treatment with corticosteroids, thiazide diuretics, oral contraceptives containing 
30 µg or greater of estrogen, immunosuppressive therapy, macrolides, antiepileptics, 
lipid-modifying agents or plant sterols. Patients were prognostically balanced at baseline 
with the following exceptions: the incidence of patients with CHD or atherosclerotic 
disease was significantly lower in the dalcetrapib 900 mg group compared to placebo 
(P<0.05) in the twelve-week study, patients in the dalcetrapib 300 and 900 mg groups 
  
had statistically significant greater BMI and age (P<0.05) as well as a greater mean lipid 
level (P<0.001) when compared to the placebo group in the four week trials.37  
 Following a four to eight week run-in period in which 113 patients were excluded 
for various reasons, the four, four-week studies evaluating dalcetrapib in individuals with 
either Type II hyperlipidemia or CHD or risk equivalents randomized 551 patients with 
intent to treat. Patients in the Type II hyperlipidemia monotherapy trial were randomized 
in 1:1 fashion to receive placebo or dalcetrapib 300, 600, or 900 mg/day. In the Type II 
hyperlipidemia combination therapy trial, patients were randomized in a 1:1:1 fashion to 
receive placebo or dalcetrapib 300 or 600 mg/day with 40 mg/day of pravastatin. In the 
CHD combination therapy trial with atorvastatin, patients were randomized in a 1:1 
fashion to receive placebo or dalcetrapib 600 mg/day with atorvastatin 20 mg/day. In the 
CHD combination therapy trial with simvastatin, patients were randomized in a 1:1 
fashion to receive placebo or dalcetrapib 600 mg/day with simvastatin 40 mg/day.37 
 Following a six to ten week run-in period in which 153 patients were excluded for 
various reasons, a total of 292 patients were randomized to receive treatment in the 
twelve-week study evaluating dalcetrapib in patients with low or average HDL-C. 
Patients taking pravastatin 40 mg/day were randomized in a 1:1:1:1 fashion to receive 
placebo or dalcetrapib 300, 600, or 900 mg/day.37 
 Outcome measures were focused on efficacy and safety of dalcetrapib. Efficacy 
was evaluated by assessing LDL-C, HDL-C, apolipoprotein A-1, triglycerides, CETP 
activity and CETP mass. The efficacy of dalcetrapib in combination therapy in the four-
week trials was pooled for analysis and included the data from the twelve-week trial up to 
four weeks with the exception of LDL-C because the patients were treated to LDL-C 
  
target. Laboratory data was measured at baseline and weeks four and twelve. The safety 
of dalcetrapib was evaluated by recording and assessing any adverse events (AE). 
Adverse events were assessed on severity, intensity, outcome, and relation to treatment. 
An AE was considered a serious AE (SAE) if it resulted in death, was life-threatening, 
resulted in hospitalization or prolonged hospitalization, resulted in serious disability or 
incapacity or required serious medical intervention including surgery to prevent one of 
the aforementioned outcomes.37  
Of the 551 patients randomized to the four-week trials, 546 were treated and 
analyzed in their respective groups. Of the 292 patients randomized to the twelve-week 
trial, 287 were treated and analyzed. A dose-dependent increase in HDL-C (P<0.001) and 
apolipoprotein A-1 (P<0.05) was observed in the monotherapy group at four weeks as 
well as in the combination therapy groups at four and twelve weeks. There was a 
significant decrease in LDL-C in the dalcetrapib 900 mg treatment group at the end of 
four weeks (-7.4 mg/dl, P<0.05). CETP activity was significantly decreased and CETP 
mass significantly increased by dalcetrapib at all doses at weeks four and twelve 
(P<0.001). All efficacy results from this trial can be found in table 3 of the specified 
study.37 
 Safety analyses of dalcetrapib revealed no significant differences between 
dalcetrapib 300 or 600 mg and placebo in the combination four-week trial in patients 
reporting one or more AE. Patients taking dalcetrapib 900 mg/day did report significantly 
more adverse events than placebo and dalcetrapib 600 mg (58% vs 42% vs 42% 
respectively, P<0.05). In the monotherapy group, there were no differences in reported 
AEs from placebo to all dalcetrapib dose groups. There were six SAEs reported in the 
  
four-week trial with no significant difference between the treatment groups and placebo. 
No deaths were reported during any of the trials. In the twelve-week trial there were 
significantly more SAEs reported in the dalcetrapib 900 mg group (n=5, 7%) compared to 
dalcetrapib 300 or 600 mg or placebo (n=1, 1%; n=2, 3%, n=1, 1%, respectively). There 
were no differences between all dalcetrapib dose groups as compared to placebo with the 
most commonly reports AEs (diarrhea, nasopharyngitis, HA, URI, cough, nausea, back 
pain, myalgias, pain in extremity, muscle spasm, abdominal distension). Withdrawal 
from treatment in the dalcetrapib groups were considered to be possibly or probably 
related to treatment, while the placebo group withdrawals were considered to be 
unrelated or remotely related. There was no dose response and a low incidence of 
reported cardiac and vascular AEs in both placebo and dalcetrapib groups. Only one 
cardiac AE (palpitations) was considered to be possibly related to treatment. There was 
no significant increase in transaminases or blood pressure in all dalcetrapib dose groups 
as compared to placebo. None of the trials were stopped early secondary to observed 
adverse events.37  
 
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week 
trial (2010) 
 Stein et al38 evaluated the safety and efficacy of the investigational CETP 
inhibitor dalcetrapib in patients with CHD or CHD risk equivalents as determined by 
NCEP ATP III guidelines. Specifically, researchers were interested in further evaluating 
dalcetrapib in patients receiving longer-term, high-dose treatment and its potential effects 
on mesenteric lymph nodes through imaging with MRI. The study was conducted in 
  
fifteen medical centers located in the United States and Germany. This was a 
randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial. 
Inclusion criteria were patients aged 18-75 years old; had CHD or CHD risk equivalents; 
had an LDL-C ≤100 mg/dl and triglycerides ≤600 mg/dl while on atorvastatin; body 
weight less than 125 kg (275 lbs). Exclusion criteria were systolic BP ≥180 mmHg; 
diastolic BP ≥ 100 mmHg; HbA1c > 10%; recent ACS or revascularization; serious 
disease of the liver, kidneys, blood, brain, or digestive tract; elevated transaminases; 
elevated creatinine phosphokinase (CPK); contraindications to MRI; mesenteric lymph 
node abnormalities; medical treatment with corticosteroids, thiazide diuretics, oral 
contraceptives containing 30 µg or greater of estrogen, immunosuppressive therapy, 
macrolides, antiepileptics, antivirals, or azole antifungals. Patients were prognostically 
balanced at baseline between the treatment and placebo groups with the exception that 
the dalcetrapib group had a significantly greater proportion of patients with coronary 
disease and atherosclerosis compared to placebo (55% vs 41% and 39% vs 33%, 
respectively). These differences were maintained at the beginning of the twenty-four 
week extension phase.38 
There were 266 patients enrolled into a five to twelve week run-in phase in which 
patients were treated with atorvastatin 10 to 80 mg/d to achieve an LDL-C less than 100 
mg/dl. Of the 266 patients in the run-in phase, 131 patients were excluded for various 
reasons. The remaining 135 patients continued treatment with atorvastatin 10-80 mg/day 
and were randomized 1:2 with intent-to-treat, to receive either placebo or dalcetrapib 900 
mg/d for twenty-four weeks, followed by an optional twenty-four week extension period. 
  
Double-blinding was maintained from the initial twenty-four week treatment period 
through the end of the extension period.38  
Patients were evaluated in clinic at baseline, weeks 2, 6, 12, 18, 24, 36, and 48, and 
at follow-up to assess efficacy and safety. Primary outcome measures for efficacy of 
dalcetrapib were changes in HDL-C from baseline at twenty-four and forty-eight weeks. 
Secondary outcomes for efficacy included the biomarkers apolipoprotein A-1, CETP 
activity and mass, and high-sensitivity C-reactive protein (hs-CRP) as well as changes in 
lipids. A primary safety outcome of this trial was to assess the effect of long-term, high-
dose dalcetrapib on mesenteric lymph node size through MRI. Patients underwent 
unenhanced, high-resolution MRI without contrast at baseline, weeks 12, 24, 36, and 48. 
The MRI scans were interpreted by a local radiologist as well as two blinded, 
independent reviewers with the primary intention of determining the size of lymph nodes 
as measured by the shortest axis. Undetectable nodes were considered to be less than 2 
mm. Lymph node sizes were recorded and compared to earlier images. Patient safety was 
assessed by monitoring reported and observed AEs and evaluating vital signs, physical 
exam and laboratory tests. Lab tests for safety included transaminases, CPK, alkaline 
phosphatase (ALP), sodium, potassium, and aldosterone levels.38 
Significant increases in HDL-C and apolipoprotein A-1 were observed in the 
dalcetrapib treatment group compared to placebo at weeks twenty-four and forty-eight. 
The increases in HDL-C and apolipoprotein A-1 in the dalcetrapib group at week twenty-
four were 12.8 mg/dl (33.4%, P<0.001) and 14.8 mg/dl (11.4%, P=0.002), respectively 
compared to 0.5 mg/dl (3.5%, P<0.001) and 4.2 mg/dl (4.4%, P=0.002), respectively in 
the placebo group. Week forty-eight saw similar differences with increases in HDL-C 
  
and apolipoprotein A-1 in the dalcetrapib group at week forty-eight were 13.8 mg/dl 
(33.8%, P<0.001) and 22.0 mg/dl (16.4%, P=0.002), respectively compared to 1.4 mg/dl 
(3.7%, P<0.001) and 9.8 mg/dl (8.2%, P=0.002), respectively in the placebo group. Of 
interest, there were small but statistically significant increases in hs-CRP levels in the 
dalcetrapib groups compared to placebo at week twenty-four, but not week forty-eight. 
Changes in hs-CRP at week twenty-four in the dalcetrapib group were 0.05mg/L (5.7%) 
compared to -0.24 mg/L (-24.2%), (P=0.010) in the placebo group. There were a total of 
70 patients in the dalcetrapib group and 33 patients in the placebo group that had a 
detectable lymph node at randomization. At week forty-eight in the placebo group, 56% 
of lymph nodes decreased in size, 41% increased in size and 3% did not change. Similar 
results were found in the dalcetrapib group, 56% decreased in size and 42% increased in 
size. There was no significant difference in the proportion of enlarged mesenteric lymph 
nodes in the two groups.38 
There was no significant difference between the percentages of patients reporting at 
least one AE in the dalcetrapib group (85%) compared to placebo (83%). There were also 
similarities in reported common AEs between the two groups. The exception would be a 
significantly greater incidence of reported diarrhea with the treatment group compared to 
placebo (17% vs 11%, respectively). Treatment-related AEs were also similar between 
dalcetrapib and placebo (39% vs 33%, respectively). Rates of serious AEs were similar 
between dalcetrapib and placebo groups as well (11% vs 9%). Of note, there was one 
report of CAD that was considered to be possibly related to dalcetrapib by the 
investigator. There were significantly more withdrawals due to AEs (12% vs 7%) and 
treatment-related AEs (9% vs 4%) in the dalcetrapib group compared to placebo. There 
  
was no significant difference in blood pressure between the two groups throughout the 
forty-eight week study. There were no significant differences between the two groups in 
regard to changes in any of the secondary safety biochemical measurements 
(transaminases, CPK, ALP, sodium, potassium, or aldosterone). There were no deaths 
throughout the forty-eight week trial.38 
 
Safety and efficacy of dalcetrapib on atherosclerotic disease using non-invasive 
multimodality imaging (dal-PLAQUE): a randomized clinical trial 
 Fayad et al39 examined the safety and efficacy of the novel CETP inhibitor 
dalcetrapib in patients with CHD or CHD risk equivalents as determined by the NCEP 
ATP III guidelines. Specifically, researchers were interested in the effects of long-term 
therapy with dalcetrapib on structural and inflammatory indices of atherosclerosis as 
measured with MRI and PET/CT imaging, respectively. This was a randomized, double-
blind, placebo-controlled phase IIb trial, conducted in eleven medical centers in the U.S. 
and Canada. Inclusion criteria were patients aged 18-75 years old; had known CHD or 
risk equivalents; plasma triglyceride concentration of 400 mg/dl or less; had LDL-C of 
100 mg/dl or less while being treated with a statin or other cholesterol-lowering 
medication unless receiving maximal dose therapy or were intolerant to statins; had a 
carotid or aortic wall to background ratio (TBR) of 1.6 or higher upon screening. 
Exclusion criteria were treatment with nicotinic acid or fibrates; uncontrolled 
hypertension or diabetes (HbA1c >10%); coronary or cerebrovascular event within past 
three months; known familial hypercholesterolemia; impaired renal function with a 
glomerular filtration rate of less than 30 ml/min; contraindications to MRI/CT/PET. 
  
Patients were prognostically balanced at baseline with the following exceptions: patients 
in the placebo group had more patients with peripheral artery disease (PAD) than those in 
the dalcetrapib group (15% vs 9%); there was a higher rate of CHD in the dalcetrapib 
group than in the placebo group (89% vs 82%); and although LDL-C was balanced, there 
was a higher rate of statin use in the placebo group than in the dalcetrapib group (92% vs 
81%).39 
 There were 189 patients entered into a pre-randomization phase that lasted up to 
eight weeks in which patients’ LDL-C was optimized to less than 100 mg/dl unless they 
were taking maximum dose therapy. Patients were screened with 
18
F-
Fluorodexoxyglucose (FDG)-PET/CT during pre-randomization. Those who met the 
required TBR of 1.6 or greater in the right carotid, left carotid or ascending aorta were 
eligible for randomization. A total of 59 individuals were excluded during pre-
randomization, leaving 130 eligible patients to be randomized in a 1:1 fashion. There 
were 64 patients randomized to treatment with dalcetrapib 600 mg/day and 66 patients 
randomized to matching placebo utilizing a computer-generated global randomization 
code. Patients remained on statin therapy and/or other lipid-lowering medications 
throughout the twenty-four month clinical trial. Double-blinding was maintained 
throughout the twenty-four month trial.39  
Co-primary end-points for the trial were MRI and PET/CT imaging. MRI was used 
to assess structural changes in the carotid arteries from baseline as measured by total 
vessel area, wall area, wall thickness, and wall area/total vessel area ratio (normalized 
wall index) as the average of left and right carotids at twenty-four months. Secondary 
MRI end-points were changes from baseline to six and twelve months in the 
  
aforementioned indices. PET/CT was used to assess change in carotid or ascending aorta 
wall uptake of 
18
F-FDG from baseline to six months, as the primary end-point change in 
TBR was measured in the most diseased 1.5 cm segment. An additional PET/CT study 
was performed solely on the carotid arteries (as an average of the carotids) for 
comparison to MRI-derived structural end-points. Secondary PET/CT endpoints were 
changes in TBR in the most diseased as determined at baseline at three and six months 
and other surrogates. Images from MRI and PET/CT were read by masked radiologists, 
two for MRI and two for PET/CT. HDL-C, LDL-C, total cholesterol, triglyceride, 
apolipoprotein A-1, and apolipoprotein B plasma concentrations were measured at 
baseline, three, six, twelve, and twenty-four months as secondary end-points. Multiple 
biomarkers assessing inflammation, oxidative stress and cardiovascular risk were 
measured at baseline, three, twelve, and twenty-four months as secondary end-points. 
Safety was assessed by monitoring reports of AEs, vital signs, electrocardiograms, and 
lab values.39  
 At twenty-four months, significant increases in HDL-C and apolipoprotein A-1 
were observed in the dalcetrapib group as compared to placebo (30.9% vs 4.0% and 
10.0% vs 3.2%, respectively). There was a significant increase in hs-CRP in the 
dalcetrapib group as compared to placebo at twenty-four weeks (33.3% vs 0.0%). As 
measured by MRI, there were no observed pro-atherogenic effects on vascular plaque 
burden with dalcetrapib. As compared to placebo, in the dalcetrapib group there was a 
decrease from baseline in total vessel area (-4.01 mm
2
, 90% CI -7.23 to -0.80), a decrease 
in wall area (-2.20 mm
2
, 90% CI -4.54 to 0.13), and an increase in normalized wall index 
(0.60%, 90% CI -1.2 to 2.5). As measured by PET/CT data, there were no observed pro-
  
inflammatory effects within the vascular system as compared to placebo after six months. 
Absolute change in the most diseased segment TBR was greater in placebo than in the 
dalcetrapib group (-0.26 vs -0.19). There was a decrease in the absolute and percentage 
changes in the dalcetrapib group as compared to placebo in the carotid arteries analysis, 
which can be found in table 5 and figure 3 of the specified study. Withdrawal from 
treatment was similar in rate and cause in both placebo and dalcetrapib groups. There was 
a total of 10 (16%) withdrawals in the dalcetrapib group and 14 (22%) in the placebo 
group. There were two deaths in the placebo group (CHD and electromechanical 
dissociation) and one in the dalcetrapib group (metastatic cancer). Treatment 
discontinuation secondary to drug-related AEs and SAEs were similar in the two groups. 
Transaminase and CPK elevations were similar in both groups. There were no significant 




 Due to the results of the ILLUMINATE trial which demonstrated an increase in 
cardiovascular events and all-cause death,24 safety concerns for CETP inhibitors remain 
at the forefront of current and ongoing research. The mechanisms in which torcetrapib 
was shown to assert its deleterious effects on patients are believed to have been mediated 
through off-target activation of the RAAS.25-28 As such, all clinical trials evaluating the 
safety of the CETP inhibitors are particularly interested in monitoring patients’ blood 
pressures, serum electrolytes and aldosterone concentrations as well as rates of CV 
events. In addition to these critical safety measures it is also important to identify and 
  
quantify the most common AEs as well as any other potentially harmful effects the 
investigational medications may have. 
 
Anacetrapib- A single study published to date evaluates the safety of anacetrapib 
in patients with known CHD or risk equivalents. The safety results from Cannon et al36 
demonstrated that there were no differences in systolic or diastolic blood pressures 
between anacetrapib and placebo. There also were no differences in serum electrolytes or 
aldosterone between the two treatment groups. An increase in cardiovascular AEs was 
not observed with treatment, in fact there were more CV events in the placebo group 
(n=21, 2.6%) compared to the treatment group (n=16, 2.0%). Revascularization rates 
were also significantly decreased with patients treated with anacetrapib (n=8) compared 
to placebo (n=28). All-cause mortality was the same between the anacetrapib and placebo 
groups (12 deaths each) at the end of the twelve-week follow-up period.36  
Previous studies of anacetrapib have determined the most common adverse events 
associated with the study medication to be gastrointestinal complaints (diarrhea, 
constipation and dyspepsia) as well as myalgias.29, 30, 32, 33, 40 There were no reported cases 
of rhabdomyolysis with treatment, and reports of myalgias were similar between the two 
groups. There were no differences in transaminases or CPK in the two groups. The safety 
and tolerability of anacetrapib appears to be comparable to that of statins41 and justifies 
further evaluation in larger populations with CHD.  
 
 Dalcetrapib- There are three published studies that have outlined the safety of 
dalcetrapib in patients with CHD or risk equivalents.37-39, 39 In all studies and all dose-
  
groups, there were no significant increases in systolic or diastolic blood pressures as 
compared to placebo. There also were no clinically significant differences in serum 
electrolytes or aldosterone in all dose-groups of dalcetrapib as compared to placebo. 
There were no significant differences and no dose-response effect on CV events with 
dalcetrapib as compared to placebo. There were however, a handful of CV events 
reported that may have been related to treatment with dalcetrapib. A myocardial 
infarction that was considered to be remotely related or unrelated to treatment with 
dalcetrapib occurred in the Stein et al (2009).37 In the same study, there was one CV 
event, palpitations, thought to be possibly related to treatment. The Stein et al (2010) 
trial38 identified a single case of CAD and two cases of hypertension thought to be 
possibly related to treatment with dalcetrapib. In contrast, there was a higher incidence of 
CV events in the placebo group as compared to the dalcetrapib group (11% vs 3%) in the 
dal-PLAQUE trial.39 Safety results from Stein et al (2009)37 found the incidence of AEs 
was significantly greater in individuals taking the highest dose of dalcetrapib (900 
mg/day). There were no deaths in either of the two Stein et al trials.37, 38 The dal-
PLAQUE trial reported two deaths in the placebo group (CHD and electromechanical 
dissociation) and one death in the dalcetrapib group (metastatic cancer).39 
 The most commonly reported AEs from the three studies included: diarrhea, 
headache, nasopharyngitis, URI, myalgias, and other muscle related symptoms.37-39, 39 In 
the Stein et al (2009) trial37 there was a higher incidence of SAEs in the dalcetrapib 900 
mg/day group compared to the other dose-groups and placebo. There were no significant 
differences in the rate of common AEs and SAEs in the Stein et al (2010) trial38 where 
patients received dalcetrapib 900 mg/day compared to placebo. The dal-PLAQUE trial39 
  
reported similarly with no differences in the rate of common AEs and SAEs in patients 
receiving dalcetrapib 600 mg/day compared to placebo. 
The safety and tolerability of dalcetrapib appears similar to that of anacetrapib. 
Although there were a small number of reported CV events that may to some degree have 
been related to treatment with dalcetrapib, these findings lack statistical significance and 
require further trials in larger populations to determine the relevance of these findings.37, 
38 Both medications have demonstrated that they do not induce the same off-target effects 
observed with torcetrapib,24, 37-39  however they both require further testing in patients 
with CHD to further demonstrate their safety in this population under long-term therapy.  
 
Efficacy and Limitations 
 Both anacetrapib and dalcetrapib have demonstrated that they are effective in 
significantly increasing HDL-C and to a lesser extent in decreasing LDL-C. However, the 
effects of anacetrapib appear to be more pronounced than those of dalcetrapib. 
Anacetrapib at a daily dose of 100 mg effectively decreased LDL-C by 39.8 % and 
increased HDL-C 138.1%.36 The lipid-modifying effects of dalcetrapib were one-quarter 
to one-half of those seen with anacetrapib.36-39 The primary lipid end-points of the three 
dalcetrapib studies can be seen in Table**. Through their lipid-modifying actions alone, 
CETP inhibitors may confer their greatest potential for reducing CV risk in individuals 
with CHD.   
  
 Anacetrapib- Independent of lipid-modification, anacetrapib appears to show 
more promise in effectively reducing CV risk in patients with known CHD. The results 
  
from Cannon et al,36 suggests that patients treated with anacetrapib may be less likely to 
require revascularization, possibly secondary to the increased efflux of cholesterol from 
the vascular wall due to  an increase in circulating anti-atherogenic HDL-C molecules. 
There were also fewer reported CV events in the anacetrapib group compared to placebo. 
Unfortunately, due to the sample size (n=1,612), one cannot definitively say that 
anacetrapib reduces the need for revascularization and or the rate of CV events.36  
In addition to sample size, there were several other limiting factors in the 
anacetrapib trial conducted by Cannon et al.36 First, a majority of the study participants 
were white. A more expansive study population including patients of other ethnic 
backgrounds should be completed to evaluate safety and drug metabolism in these 
populations. Second, the length of the trial stands as another limitation in this study’s 
design. Longer trials will be needed in the future to establish long-term safety and 
efficacy data on patients taking anacetrapib. Third, the study participants were receiving 
concomitant treatment with several different statins. The study adjusted for this by 
matching the number of participants taking each of the various types of statins in the 
placebo and treatment groups. This study was likely designed as such due to previous 
studies having already described the safety and efficacy of anacetrapib when paired with 
specific statins.29, 42 While this method of testing the efficacy of anacetrapib in 
conjunction with various types of statins is more reflective of how the medication will be 
used in practice, more control over the types of statins that patients were taking would 
have produced a study with less confounding variables. Fourth, the study protocol 
required any patient with LDL-C below the 25 mg/dl threshold to be withdrawn from the 
study medication, with patients expected to complete safety follow-up through the 
  
twelve-week post-treatment phase. There is no long-term data evaluating the possible 
safety concerns associated with individuals with LDL-C below 25 mg/dl. Finally, the 
study is industry sponsored by Merck® thereby introducing possible bias into data 
collection and analysis.36  
 
 Dalcetrapib- The most promising evidence for dalcetrapib in reducing CV risk 
independent of its lipid-modifying properties comes from the dal-PLAQUE study39.{{30 
Fayad,Z.A. 2011}} An absolute difference of -4.01 mm (-7.23 to -0.80, 90% CI) in total 
vessel area, a decrease in wall area (-2.20 mm
2
, 90% CI -4.54 to 0.13), and an increase in 
normalized wall index (0.60%, 90% CI -1.2 to 2.5) were observed in the dalcetrapib 
group as compared to placebo after twenty-four months of treatment. This suggests a 
possible anti-atherogenic effect of dalcetrapib with reversal of atherosclerosis via the 
reverse cholesterol transport pathway. There was also a decrease in the absolute and 
percentage changes in the dalcetrapib group as compared to placebo in the carotid artery 
analysis. However, there was a more pronounced decrease in metabolic activity in the 
most diseased segment of patients’ index vessels with placebo than with anacetrapib at 
six months (-0.26 and -0.19 respectively). Although this data was underpowered (P=0.51) 
and considered to be within the predetermined limits of no harm by the study’s design, it 
is of concern due to the correlation between inflammation in the vascular system and the 
progression of atherosclerotic plaques.43, 44 The results of the dal-PLAQUE trial39 are 
promising, however due to the size of the study population (n=130), definitive 
conclusions cannot be drawn regarding the efficacy of dalcetrapib in reducing the 
atherosclerotic burden in patients with CHD.  
  
 The dal-PLAQUE trial39 had several other significant limitations in addition to the 
lack of a large sample population. First and most notably, it is important to recognize that 
this study is significantly underpowered and lacks statistically significant confidence 
intervals; this again is a product of the small sample size. Second, the primary end-points 
of this study are based solely on non-invasive imaging techniques. There is the potential 
for inter and intra-user variability in interpreting results from images. The study designers 
tried to limit this variability by utilizing two different, blinded readers for each of the 
imaging modalities. Additionally, the study report did not address how differences in 
image interpretations were accounted for. Third, the favorable results from the PET/CT 
scan were identified on comparison of carotid artery analysis, but not seen in images 
taken from the index vessels. The authors make a note of the possibility of MRI being 
more sensitive in detecting structural changes in the smaller carotid arteries as compared 
to the larger ascending aorta which was the predominant index vessel. Fourth, the study 
participants were receiving concomitant treatment with several different statins and or 
other lipid-lowering medications. The study report did not address this issue, as such 
there is no way to know whether participants were matched based on the type of statin 
they were taking. This confounding variable could have potential effects on study 
outcomes as there may be variability among statins in their ability to reduce vascular 
inflammation.45-47 Finally, the study is industry sponsored by Roche® thereby introducing 
possible bias into data collection and analysis. 
 Limitations of the two clinical trials evaluating the safety and tolerability of 
dalcetrapib have similar limitations to the aforementioned studies. First, both studies are 
limited by the small sample sizes (n=833 and n=135).** Secondly, both studies are too 
  
short in duration to be able to determine the potential long-term safety and efficacy 
concerns of a new medication. Finally, both studies again are industry sponsored by 
Roche® thereby introducing possible bias into data collection and analysis.39  
CONCLUSION 
 Cardiovascular disease remains an unequivocal burden on health care systems 
worldwide. As such, interest in developing new strategies and medications for the 
prevention of CVD remains important as ever. Current treatment guidelines recommend 
the use of statins to treat dyslipidemic patients with low HDL-C, yet significant risk 
remains in those individuals who achieve ideal LDL-C levels and whose HDL-C remains 
low. 6-8  The new class of CETP inhibitors has established itself as being exceedingly 
more efficacious at increasing HDL-C levels than the current options of statins, fibrates 
and nicotinic acid.48 Phase I and II clinical trials in both anacetrapib and dalcetrapib have 
demonstrated that both medications have a good safety profile and are potent inhibitors of 
CETP however, the results from Phase III clinical trials will be the deciding factor as to 
whether either of these medications will be approved for treatment of the general 
population.  
 There are two ongoing Phase III clinical trials evaluating the long-term safety and 
efficacy of anacetrapib and dalcetrapib in large populations. The REVEAL (Randomized 
EValuation of the Effects of Anacetrapib Through Lipid-modification) trial49 is currently 
enrolling an estimated 30,000 participants with known vascular disease. The trial is 
designed to evaluate how effective anacetrapib 100 mg/daily is at preventing CV events 
(coronary death, MI or revascularization) in individuals with preexisting  CVD over a 
mean follow-up period of four years. The estimated completion date of the REVEAL trial 
  
is January 2017.  The dal-OUTCOMES trial50 is an ongoing study which has enrolled an 
estimated 15,600 participants with stable CHD who have recently experienced ACS. The 
trial is designed to evaluate how effective dalcetrapib 600 mg/daily is at preventing 
secondary events (any CV morbidity or mortality) in individuals with recent ACS over a 
mean follow-up period of two years. The estimated completion date of the dal-
OUTCOMES trial is May 2013. In addition to the ongoing clinical trials with anacetrapib 
and dalcetrapib, a third CETP inhibitor evacetrapib is being developed by Eli Lilly® and 
is currently recruiting for early phase clinical trials.51 
The promising results from phase I and II clinical trials have made CETP inhibitors 
a novel therapy in treating dyslipidemia however; their role is yet to be determined.  As 
monotherapy they are impressively effective at augmenting HDL-C, which makes them 
ideal pharmaceutical agents for treating individuals with isolated low HDL-C. Although 
CETP inhibitors have a much less pronounced effect on LDL-C than do statins, they 
make ideal agents for adjunct therapy. There is however a possibility of achieving 
dangerously low LDL-C with co-administration and further research must elucidate the 
possible sequelae and or ideal dosing regimens with statins to maintain patient safety.36 
Ultimately, the goal of pharmacotherapy in patients with CHD is to prevent CV events. If 
the ongoing phase III clinical trials demonstrate a decrease in CV risk, CETP inhibitors 
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Table I: Characteristics of Reviewed Studies 
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-44.5% vs        
-4.8% 
152.8% vs 14.7% 
Total CV events; 900 mg 16 (2.0%) 
vs 21 (2.6%), Revascularization; 8 
(1.0%) vs 28 (3.5%) 
- 
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-4.88% 
14.01% vs -0.03% 
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-4.88% 
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4 weeks N=72 n/a 
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-0.5% vs 5.6% 33.4% vs 3.5% n/a§ 
No clinically or statistically 
significant changes in node size. 



















3.8% vs 3.9% 33.9% vs -0.8% 
2 (3%) vs 7 (11%) 
MRI carotid total vessel area 
absolute change compared to 
placebo:  -4.01mm 
11 (17%) vs 18 (28%) 
24 
months 
0.1% vs 7.3% 30.9% vs 4.0% 
PET/CT 18F-FDG uptake 
absolute change index vessel:     
-0.19 vs -0.26 
 *Includes cardiac AEs and SAEs, respectively. †Results from monotherapy studies not included. §Reported cardiac and vascular AEs possibly related to treatment with 
dalcetrapib 900 mg/d were: one case of CAD and two cases of hypertension. ‡Number of patients (N) reported as measured at time of statistical analysis of end-points.  
Table II: Summary of Findings 
  




Figure 1. Triglycerides derived from the intestine are transported via chylomicrons, or synthesized de novo in the 
liver and transported via VLDL. Triglyceride-rich VLDL is hydrolyzed via lipoprotein lipase (LPL) and other 
lipolytic enzymes and subsequently converted into LDL, which is rich in cholesterol esters (CE). Cholesterol-rich 
LDL particles can then bind to cell LDL receptors (LDL-R) in hepatic or peripheral tissues (including arterial wall 
macrophages) to transfer cholesterol esters into these cells. Cholesterol that is transferred to peripheral tissues via 
LDL is frequently oxidized during this process. Reverse cholesterol transport allows free cholesterol (FC) to be 
removed from peripheral tissues (including arterial wall macrophages) via a number of mechanisms, including ATP 
binding cassette A1 (ABC A1), ATP binding cassettes G1 and G4 (ABC G1 and ABC G4), and via the scavenger 
pathway through scavenger receptor B1 (SR B1). Free cholesterol is then transferred to either a mature α-HDL 
molecule, or a nascent pre β-HDL molecule. Pre β-HDL molecules are rich in free cholesterol and phospholipids 
(PL). The free cholesterol bound to pre β-HDL is esterified via lecithin cholesterol acyltransferase (LCAT) which 
will force the maturation of the discoid molecule into a spherical α-HDL. Mature α-HDL can then transfer 
cholesterol from the periphery back to the liver via SR B1 receptors, where cholesterol can be recycled or excreted 
into bile. Cholesteryl ester transfer protein (CETP) mediates the transfer of lipoproteins by exchanging triglycerides 
from VLDL to HDL in exchange for cholesterol esters from HDL to VLDL and LDL. The net effect of CETP 
activity is the loss of CEs from the antiatherogenic HDL molecules to the proatherogenic LDL and VLDL 
molecules, whereby cholesterol can undergo oxidation and contribute to the vascular plaque burden. 
 
 
 
 
 
 
